AllianceBernstein
VTVT icon

AllianceBernstein’s vTv Therapeutics VTVT Stock Holding History

AllianceBernstein’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-265
Closed -$19K – 3211
2020
Q3 		$19K Sell
265
-50
-16% -$4.39K ﹤0.01% 3148
2020
Q2 		$28K Buy
+315
New +$31.1K ﹤0.01% 3181

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAG
Winthrop Advisory Group Boston, Massachusetts $1.48B AUM 22.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

AllianceBernstein's VTVT Position: Q4 2020 in Review

AllianceBernstein sold out of vTv Therapeutics (VTVT) in Q4 2020, closing a stake of 265 shares — an estimated $19K sold.

AllianceBernstein first reported a position in VTVT in Q2 2020 and held it in 2 quarters. The position peaked at $28K in Q2 2020. 44 funds tracked by Wall St. Rank hold VTVT as of Q4 2020.

  • AllianceBernstein reported no remaining vTv Therapeutics position as of Q4 2020 after selling out during the quarter.
  • AllianceBernstein sold 265 vTv Therapeutics shares in Q4 2020, an estimated $19K.
  • AllianceBernstein first reported a position in vTv Therapeutics in Q2 2020 and held it in 2 quarters.
  • AllianceBernstein's vTv Therapeutics position peaked at $28K in Q2 2020.
  • 44 funds tracked by Wall St. Rank held vTv Therapeutics as of Q4 2020.

Based on AllianceBernstein's 13F filing for Q4 2020, filed 8 Feb 2021.